 | • レポートコード：MRC2203A739 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界の痔瘻治療市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（外科的、非外科的）分析、用途別（括約筋間瘻、経括約筋瘻、括約筋瘻、その他）分析、エンドユーザー別（病院、外来手術センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の痔瘻治療市場規模：治療別（外科的、非外科的） ・世界の痔瘻治療市場規模：用途別（括約筋間瘻、経括約筋瘻、括約筋瘻、その他） ・世界の痔瘻治療市場規模：エンドユーザー別（病院、外来手術センター、その他） ・世界の痔瘻治療市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Pfizer, Inc.、Cook Medical、KARL STORZ SE & Co. KG、...） ・市場機会・将来の傾向 |
The anal fistula treatment market will show a rapid growth due to the rising cases of inflammatory bowel diseases such as crohn’s disease and ulcerative colitis, launch of new products and growing demand of non-surgical methods such as fibrin glue injection, adipose-derived stem cells therapy.
There has been an increasing prevalence of anal fistula cases as it remains a perplexing condition for the colorectal surgeon. As per GBD 2017 Inflammatory Bowel Disease Collaborators, there were 6.8 million cases of inflammatory bowel disease IBD globally. The age-standardised prevalence rate increased from 79.5per 100000 population in 1990 to 84.3 per 100 000 population in 2017.
In addition, there is a rise in demand for safe and effective treatment with no chance of recurrence and fewer side effects that is propelling the key industry players to introduce advanced drugs and devices.
Key Market Trends
Surgical is Expected to Dominate the Anal Fistula Treatment Market of Treatment Type Segment During the Forecast Period
The surgical treatment for an anal fistula is found to be associated with low recurrence rates, minimal incontinence and good quality of life. The best option is found to depend on the position of fistula and whether it’s a single channel or branches off in different directions. Surgical procedures include fistulotomy, bioprosthetic plugs, advancement flap procedures, seton techniques, and new techniques such as LIFT and FiLaC therapy. The most common type of surgery for anal fistulas is a fistulotomy.
The surgical segment is found dominating the anal fistula treatment market due to the increasing incidences of fistula induced infections, rise in demand of safe and effective treatment helps to drive the overall market.
North America is Found Leading the Anal Fistula Treatment Market
North America is found dominating the anal fistula market due to a large number of patient population with inflammatory bowel diseases, early adoption of new technologies, and high health care expenditure by the public and private sectors in the United States. There are approximately 70,000 new cases of IBD being diagnosed every year in the United States, and this high rate of IBD cases are increasing every year that has helped in the overall growth of the market. However, increasing demand for anal fistula treatment is creating opportunities and increasing awareness about the treatment in the market.
In Asia Pacific region, there is also an increased incidence of conditions such as Crohn’s disease and increased awareness about these conditions that are expected to propel the anal fistula treatment market during the forecast period.
Competitive Landscape
The presence of a considerable number of companies is found significantly contributing to market growth. Market players are actively participating in new product launches, collaboration and development to expand their market share. For instance, in February 2018, AMI has launched FiXcision instrument, which consists of the guide, circular blade, probe and base plate for the precise treatment of anal fistulas.
Key players in the anal fistula treatment market are Cook Medical, KARL STORZ SE & Co. KG, Medtronic plc, Pfizer Inc., W. L. Gore & Associates, Inc., Biolitec AG and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Cases of Inflammatory Bowel Diseases (IBD) Such As Crohn’s Disease and Ulcerative Colitis
4.2.2 Launch of New Products
4.2.3 Growing Demand of Non-Surgical Methods Such as Fibrin Glue Injection, Adipose-derived Stem Cells Therapy
4.3 Market Restraints
4.3.1 High Cost Associated With the Procedure
4.3.2 Lack of Awareness about Anal Fistula Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Treatment Type
5.1.1 Surgical
5.1.2 Non Surgical
5.2 By Application
5.2.1 Intersphincteric Fistula
5.2.2 Transsphincteric Fistula
5.2.3 Suprasphincteric Fistula
5.2.4 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Ambulatory Surgical Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Cook Medical
6.1.3 KARL STORZ SE & Co. KG
6.1.4 Medtronic plc
6.1.5 AstraZeneca Plc
6.1.6 W. L. Gore & Associates, Inc (Gore Medical)
6.1.7 Biolitec AG
7 MARKET OPPORTUNITIES AND FUTURE TRENDS